Piramal Pharma Installs Solar Plant in UK

Piramal Pharma Solutions is deploying a 4.3 MWp ground-mounted solar power plant at its integrated facility in Morpeth, United Kingdom. The installation is designed to generate approximately 3,950 MWh of renewable electricity annually, which the company states will satisfy roughly 22% of the site’s total annual power consumption. This move represents a direct operational adjustment to the site's energy sourcing strategy, shifting a significant portion of load from the grid to on-site generation.

The physical infrastructure comprises around 6,200 solar panels distributed across 16 acres of land at the manufacturing site. According to the project data, the clean energy produced is sufficient to power approximately 1,460 UK households per year. By securing this local generation capacity, Piramal Pharma Solutions aims to stabilize its energy inputs while simultaneously advancing its corporate decarbonization targets for its drug substance and drug product operations.

Power Purchase Agreement Structure

The project is being executed under a Power Purchase Agreement with Alight UK BTM1 Limited, identified as a solar developer and independent power producer. This contractual framework allows the facility to secure a predictable stream of renewable energy without necessarily bearing the full upfront capital expenditure of the installation. The agreement ties the site's operational output to a specific third-party developer, creating a long-term energy supply relationship that supports the CDMO’s manufacturing continuity.

By formalizing this arrangement, Piramal Pharma Solutions locks in a renewable energy source that aligns with its broader environmental, social, and governance commitments. The PPA structure ensures that the 3,950 MWh annual output is contractually available to the Morpeth facility, providing a tangible mechanism for reducing reliance on non-renewable grid electricity. This approach reflects a common industry trend where manufacturing firms seek to decouple their operational carbon footprint from external market volatility.

Projected Carbon Reduction Impact

The operational impact of the new plant is quantified in terms of avoided emissions over a 25-year period. Piramal Pharma Solutions estimates that the installation will prevent the release of approximately 20,000 tonnes of CO2 equivalent. This figure serves as a key metric for the company's sustainability reporting, linking the physical installation of the solar panels directly to a measurable reduction in its environmental impact.

The initiative was reported by GN auto stocks/utilities: power plant, highlighting the intersection of pharmaceutical manufacturing and utility-scale renewable energy deployment. For the Morpeth site, the shift to on-site solar generation marks a concrete step in its decarbonization roadmap, translating abstract climate goals into specific engineering and financial commitments. The project underscores how large-scale CDMOs are increasingly integrating energy infrastructure into their core facility planning.

Site Energy Demand Context

The 22% coverage figure indicates that the Morpeth facility remains dependent on external grid power for the majority of its operations. The solar plant addresses a substantial segment of this demand, but the remaining 78% will continue to be sourced from conventional or other renewable grid supplies. This partial offset strategy allows the company to make immediate progress on its energy mix while maintaining the flexibility to scale further as technology costs decline or regulatory requirements tighten.

The scale of the installation, spanning 16 acres with 6,200 panels, reflects the high energy intensity of pharmaceutical manufacturing processes. By dedicating significant land area to power generation, Piramal Pharma Solutions demonstrates a commitment to long-term energy security and sustainability. The project stands as a tangible asset on the company's balance sheet, contributing to its operational resilience and environmental profile in the competitive CDMO market.